It’s tough when something that used to be a given, like young students getting a particular vaccine, starts to falter. There was a time when a lot more first-year students eagerly rolled up their sleeves, but those numbers have dipped. While there’s been a valiant effort to bounce back, we haven’t quite reached those earlier, higher levels. It’s a bit like trying to fill a bucket with a small leak – you can pour water in, but some still escapes. Fine Gael Senator Martin Conway, a keen observer of public health, recently raised this very question: why isn’t the uptake higher? Dr. Colm Henry, the HSE’s chief clinical officer, didn’t mince words, pointing to “disinformation” as a significant culprit. It’s truly disheartening to think that misleading information can stand in the way of protecting our young people. Dr. Lucy Jessop, also from the HSE, assured everyone that they’re not sitting idly by. They’re actively working to encourage more teenagers to take advantage of this protection, emphasizing that the sweet spot for vaccination is before the age of 15. To catch up on missed opportunities, a special program is now in full swing for fifth and sixth-year students, and they’ve even extended its availability into the summer months, making it as accessible as possible. It’s a bit like offering extra credit to make sure everyone has a fair chance to succeed.
Beyond the younger generation, a spotlight also shone on an issue affecting older people: the shingles vaccine. Officials from both the HSE and the Department of Health were pressed on why this crucial vaccine isn’t yet freely available to our seniors. Dr. Mary Horgan, the chief medical officer, readily affirmed its safety and effectiveness, leaving no doubt about its benefits. However, she framed the core challenge as one of “affordability” – a common hurdle in healthcare. Adding another layer of complexity, there have been whispers and claims that the shingles vaccine might also help reduce the risk of dementia. Dr. Horgan, ever the pragmatist, clarified that while it’s an intriguing idea, the vaccine is currently only licensed to protect against shingles. Its potential role in dementia is, indeed, being explored as part of a much broader study, which means we’ll have to wait for conclusive evidence. She also shared some good news with Labour TD Marie Sherlock, explaining that the Department is actively collaborating with the HSE to identify if there are specific segments of the population who could be offered the vaccine without cost. Dr. Henry, always thinking about those most vulnerable, suggested that individuals with weakened immune systems could be prime candidates for prioritized vaccination, should the HSE decide to cover the cost. It’s about ensuring that those who need it most aren’t left behind due to financial barriers or other challenges.
Dr. Henry then painted a much brighter picture when discussing the broader impact of vaccination programs, underscoring the incredible work done this past winter. He spoke with a palpable sense of pride about how their winter vaccine program had been a shield for over a million people, guarding them against the severe complications of seasonal flu. The numbers were truly impressive: almost 50,000 more children protected than the previous year, and they successfully surpassed their targets for the most vulnerable among us – those over 80 and residents in long-term care facilities, achieving remarkable vaccination coverage rates of 91% and 83% respectively. This isn’t just about statistics; it’s about countless families spared from worry and illness. He also highlighted the success in protecting newborns and infants under six months from the dangers of RSV infection through Nirsevimab immunization. An incredible 88% of newborns received this protection, with 52% in the catch-up group, effectively reducing RSV-related pediatric hospital admissions. He pointed to a striking 60% drop in emergency department visits and a 71% reduction in Pediatric Intensive Care Unit (PICU) admissions witnessed during their first RSV Pathfinder program. While the evaluation of the most recent program is still ongoing, the initial results speak volumes about the power of proactive public health measures. It’s a testament to how dedicated effort can truly make a difference in the lives of the youngest and most delicate members of our society.
However, the conversation wasn’t entirely about triumphs. A note of concern emerged as Dr. Henry addressed the declining uptake rates within the Primary Childhood Immunization program. These rates, he noted, continue to linger below the 95% WHO target, which is crucial for achieving herd immunity – that invisible shield that protects everyone, especially those who can’t be vaccinated. To put it into perspective, the uptake for the MMR vaccine, measured at 24 months of age, stands at 87.6%, and for the 6-in-1 vaccine, it’s 90.4%. While these numbers are still significant, falling short of the target means we’re not fully harnessing the power of collective protection. It’s a reminder that even with successful programs, vigilance and continuous effort are essential to maintain public health standards. Interestingly, amidst these discussions, plans are afoot to introduce a selective BCG program in 2026, targeting infants under 12 months in higher-risk groups as part of the HSE National TB Strategy. This strategic rollout shows a commitment to adapting and evolving public health initiatives to meet specific needs and challenges, demonstrating a forward-thinking approach even while addressing current shortfalls.
The discussion then shifted to broader policy, with a powerful statement from a spokesperson for GSK, the pharmaceutical company that produces the shingles vaccine. They articulated a clear “public health need for a Shingles National Immunisation Programme,” making a compelling case for its implementation. It’s not just an idea; it’s a reality in other parts of Europe. Fifteen European countries have already embraced national immunization programs for shingles, and these initiatives are not just about health; they’re also about smart investment. The spokesperson highlighted that these programs deliver a “recognised return on investment,” safeguarding both the health and the dignity of older citizens. It’s a win-win, showing that prioritizing public health can also be financially prudent in the long run. GSK expressed its full commitment to collaborating with the State, emphasizing the importance of ensuring “equitable access to vaccination for all at-risk populations.” They firmly believe that the offer they extended to the Department of Health could have paved the way for a Shingles National Immunisation Programme to be successfully implemented, suggesting a missed opportunity. This resonates deeply, as access to vital medical protection shouldn’t be a luxury.
Finally, the dialogue circled back to the overarching policy framework, with a reference to the Programme for Government. This program, it was noted, includes a recommendation to expand the national immunization program in line with NIAC guidelines. This is a crucial point, underscoring the official recognition of the need for growth and adaptation in vaccination strategies. The GSK spokesperson concluded with a powerful sentiment: “it is vital that we ensure that the success observed in our paediatric programme follows through to the adult population to promote an equitable, life-course approach.” This isn’t just about vaccinating children; it’s about embracing a holistic view of health throughout a person’s entire life. It means ensuring that the robust and successful vaccination efforts for the young are mirrored by equally comprehensive programs for adults, particularly as they age and face new health challenges. This “life-course approach” advocates for continuous protection, recognizing that health is a lifelong journey, and that vaccination plays a critical role at every stage. It’s a call to action, urging us to extend the same level of care and protection to every generation, ensuring that no one is left vulnerable due to age or circumstance.